Mr. Chair, in the balance of the agreement, on the pharmaceutical provisions and the intellectual property provisions, there were elements that were specifically in the CETA text, and then there were portions that were fundamental to the balance we struck for the Canadian implementation. One of them was actually ending dual litigation, which was a fundamental ask of stakeholders within the overall process.
Your motion reflects or expresses the views of CGPA, but our view is that it's overbroad. This is actually a necessary provision to allow for the ending of dual litigation. It's fundamental to the implementation as articulated.